Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aprea Therapeutics, Inc. APRE

Healthcare  —  Biotechnology
0.76 (0.02) (2.56%) as of 25 Sep
Market cap
$9.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Aprea Therapeutics, Inc. (APRE) Business Profile

Updated before January 2025

Company Overview

Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel cancer therapeutics. Founded in 2002 and headquartered in Boston, Massachusetts, Aprea focuses on leveraging the tumor suppressor protein p53 pathway to create innovative treatments for cancer patients. The company’s leadership team comprises seasoned professionals with extensive experience in oncology drug development and commercialization. Key executives include Christian S. Schade, who serves as the Chairman and Chief Executive Officer, and Eyal Attar, M.D., the Chief Medical Officer. Their combined expertise drives Aprea’s mission to address unmet medical needs in oncology.

Core Business Segments

Aprea Therapeutics operates primarily in the field of oncology, with a focus on developing small-molecule therapeutics targeting the p53 tumor suppressor pathway. The company’s core business segments include:

1. Small-Molecule Therapeutics

  • Eprenetapopt (APR-246): Aprea’s lead product candidate, eprenetapopt, is a first-in-class small molecule designed to reactivate mutant p53 protein. It is being developed for the treatment of hematologic malignancies and solid tumors. Clinical trials have shown promising results in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
  • APR-548: Another small-molecule therapeutic in Aprea’s pipeline, APR-548, is a second-generation p53 reactivator currently in preclinical development. It aims to provide enhanced efficacy and safety compared to its predecessor.

2. Combination Therapies

Aprea is also exploring the potential of combining eprenetapopt with other cancer therapies, such as immune checkpoint inhibitors and chemotherapy, to enhance treatment outcomes. These combination therapies are being evaluated in various clinical trials.

Business Model

Aprea Therapeutics operates on a research-driven business model that integrates cutting-edge science with clinical development to create innovative cancer treatments. The company generates revenue primarily through partnerships, licensing agreements, and potential future product sales. Key aspects of its business model include:

  • Research and Development (R&D): Aprea invests heavily in R&D to advance its pipeline of p53-targeted therapies. The company collaborates with academic institutions and research organizations to accelerate drug discovery and development.
  • Clinical Trials: Aprea conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates. Positive trial results pave the way for regulatory approvals and commercialization.
  • Strategic Partnerships: The company seeks partnerships with pharmaceutical and biotechnology firms to co-develop and commercialize its therapies, thereby expanding its market reach.

Strategic Direction

Aprea Therapeutics is committed to advancing its pipeline of p53-targeted therapies and exploring new therapeutic areas. Key strategic priorities include:

  • Pipeline Expansion: Aprea aims to expand its pipeline by developing next-generation p53 reactivators and exploring additional indications for its existing product candidates.
  • Global Market Penetration: The company plans to establish a strong presence in key markets worldwide through strategic partnerships and collaborations.
  • Sustainability Goals: Aprea is dedicated to conducting its operations in an environmentally and socially responsible manner. The company prioritizes sustainability in its research and manufacturing processes.
  • Innovation in Oncology: Aprea continues to invest in cutting-edge technologies and research to stay at the forefront of oncology drug development.

Competitive Landscape

Aprea Therapeutics operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Pharmaceutical Giants: Companies like Roche, Novartis, and Merck are major players in the oncology space, offering a wide range of cancer therapies.
  • Biotechnology Firms: Smaller biotech companies such as Blueprint Medicines, Mirati Therapeutics, and Zymeworks also focus on developing targeted cancer therapies.
  • Academic and Research Institutions: Universities and research organizations conducting oncology research pose indirect competition by advancing alternative therapeutic approaches.

Aprea differentiates itself through its unique focus on the p53 pathway and its innovative small-molecule therapeutics.

Risk Factors

Like any biopharmaceutical company, Aprea Therapeutics faces several risks, including:

  • Regulatory Challenges: The company’s product candidates must undergo rigorous regulatory review, and there is no guarantee of approval.
  • Market Dependence: Aprea’s success depends on the commercial viability of its lead product candidates, particularly eprenetapopt.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, making it vulnerable to supply chain disruptions.
  • Competition: Intense competition in the oncology space could impact Aprea’s market share and profitability.
  • Financial Risks: As a clinical-stage company, Aprea has limited revenue streams and relies on external funding to support its operations.

Recent Developments

Aprea Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Updates: The company announced positive interim results from its Phase 3 clinical trial of eprenetapopt in combination with azacitidine for the treatment of MDS.
  • Partnerships: Aprea entered into a collaboration with a leading pharmaceutical company to explore combination therapies involving eprenetapopt.
  • Corporate Restructuring: To streamline operations and focus on core priorities, Aprea implemented a corporate restructuring plan, resulting in cost savings and increased efficiency.
  • COVID-19 Impact: The global pandemic posed challenges to clinical trial enrollment and supply chain operations, but Aprea successfully adapted to these disruptions.

Investment Considerations

Investors considering Aprea Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: Aprea’s focus on the p53 pathway positions it as a leader in targeted cancer therapies.
  • Experienced Leadership: The company’s management team has a proven track record in oncology drug development.
  • Strategic Partnerships: Collaborations with industry leaders enhance Aprea’s market potential.

Risks

  • Clinical and Regulatory Uncertainty: The success of Aprea’s product candidates depends on positive clinical trial results and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, Aprea relies on external funding to sustain its operations.
  • Market Competition: Intense competition in the oncology space could impact Aprea’s growth prospects.

Conclusion

Aprea Therapeutics, Inc. is a pioneering biopharmaceutical company with a strong focus on developing innovative cancer therapies targeting the p53 pathway. While the company faces challenges typical of clinical-stage firms, its promising pipeline, experienced leadership, and strategic partnerships position it for long-term success. As Aprea continues to advance its product candidates and expand its market presence, it remains a compelling player in the oncology space with significant growth potential.